ctDNA tumor fraction in TALAPRO-3 from @AzadOncology at #ESMO26 🧬 In HRR-deficient mCSPC, baseline ctDNA+ (TF ≥1%) was prognostic for rPFS in both arms. Week 5 matters too: 82% of ctDNA+ patients cleared on TALA + ENZA vs 68% on PBO + ENZA, and clearance tracked with longer rPFS (HR 0.36 vs persistent ctDNA+). Early on-treatment ctDNA could become a real tool for risk stratification and monitoring. Next up is whether it adds value beyond PSA. #MRD #ctDNA #ProstateCancer
256 views · 5 likes · 5 reposts · 0 replies
Utility of ctDNA tumor fraction (TF) as a prognostic biomarker in TALAPRO-3: phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in patients (pts) with homologous recombination repair (HRR) gene–mutated metasta
https://esmocongress.esmo.orgPlasma ctDNA as standalone or adjunct to tumour tissue for HRR and PI3K/AKT genotyping in mCRPC: PROMPT (NCT04746300)
https://esmocongress.esmo.orgCharacterizing resistance mechanisms and predictors of early progression and long-term response to lorlatinib: Circulating tumor DNA (ctDNA) analyses from the CROWN study
https://esmocongress.esmo.orgClinical utility of reflex liquid comprehensive genomic profiling (LCGP) to complement tumor-informed circulating tumor DNA (ctDNA) monitoring in solid tumors
https://esmocongress.esmo.orgctDNA analysis of the Phase 3 KEYNOTE-B15 trial: neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) + pembrolizumab (pembro) for participants (pts) with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin
https://esmocongress.esmo.orgUltrasensitive monitoring of early ctDNA dynamics during neoadjuvant treatment in early-stage triple-negative breast cancer: Pre-interim results from the B-STRONGER-I study
https://esmocongress.esmo.orgSource: Alan Tan · x.com